Table 1.

In vitro antiproliferative activity of hybrids 4a–n and 7a–d against MDA-MB-231 and MCF-7 breast cancer cell lines.

Compound	R	R1	IC50 (µM) a
			MDA-MB-231	MCF-7
4a	H	H	NA b	NA b
4b	5-F	H	108.3 ± 8.2	58.5 ± 3.2
4c	5-Cl	H	24.1 ± 2.1	29.2 ± 2.5
4d	5-Br	H	15.7 ± 0.9	17.1 ± 1.1
4e	5-OCH3	H	42.6 ± 3.4	52.9 ± 5.0
4f	5-CH3	H	60.9 ± 4.2	22.8 ± 2.0
4g	5,7-(CH3)2	H	43.6 ± 3.1	47.4 ± 3.9
4h	H	CH3	51.7 ± 2.1	56.0 ± 3.7
4i	5-F	CH3	152.1 ± 11.5	104.9 ± 7.5
4j	5-Cl	CH3	50.8 ± 3.5	NA b
4k	5-Br	CH3	NA b	NA b
4l	5-OCH3	CH3	47.1 ± 4.1	53.5 ± 3.6
4m	5-CH3	CH3	7.6 ± 0.5	8.4 ± 0.5
4n	5,7-(CH3)2	CH3	36.3 ± 2.9	23.7 ± 1.9
7a	5-Cl	-	47.2 ± 3.8	127.3 ± 9.9
7b	5-OCH3	-	13.2 ± 1.7	21.7 ± 1.5
7c	5-CH3	-	40.3 ± 2.5	48.2 ± 2.7
7d	5,7-(CH3)2	-	23.5 ± 1.0	27.6 ± 2.4
Dox.			4.7 ± 0.4	3.8 ± 0.4
Sunitinib			5.5 ± 0.5	3.4 ± 0.3

^a IC₅₀ values are the mean ± S.D. of three separate experiments; ^b NA: Compounds having IC₅₀ value > 200 µM.